Cogent Biosciences, Inc. Revenue from Contract with Customer, Including Assessed Tax
Cogent Biosciences, Inc. (COGT) reported Revenue from Contract with Customer, Including Assessed Tax of $7.87 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-15.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2022-03-15
- Cogent Biosciences, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- Cogent Biosciences, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2020-09-30 was $312.00K, a 69.41% decline year-over-year.
- Cogent Biosciences, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2020-06-30 was $528.00K, a 83.17% decline year-over-year.
- Cogent Biosciences, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2020-03-31 was $7.03M, a 130.30% increase year-over-year.
- Cogent Biosciences, Inc. revenue from contract with customer, including assessed tax for fiscal 2020 was $7.87M, a 65.02% decline from fiscal 2019.
- Cogent Biosciences, Inc. revenue from contract with customer, including assessed tax for fiscal 2019 was $22.50M, a 131.14% increase from fiscal 2018.
- Cogent Biosciences, Inc. revenue from contract with customer, including assessed tax for fiscal 2018 was $9.73M, a 16.44% increase from fiscal 2017.
- Cogent Biosciences, Inc. revenue from contract with customer, including assessed tax for fiscal 2017 was $8.36M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $312.00K derived: sum of 2 quarters · filed 2022-03-15 | $840.00K derived: sum of 3 quarters · filed 2022-03-15 | $7.87M 10-K · filed 2022-03-15 |
| 2020-09-30 | $312.00K 10-Q · filed 2021-11-10 | $840.00K derived: sum of 2 quarters · filed 2021-11-10 | $7.87M 10-Q · filed 2021-11-10 | $23.16M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $528.00K 10-Q · filed 2021-08-16 | $7.56M 10-Q · filed 2021-08-16 | $22.85M derived: sum of 3 quarters · filed 2021-08-16 | $23.87M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $7.03M 10-Q · filed 2021-05-12 | $22.32M derived: sum of 2 quarters · filed 2021-05-12 | $23.34M derived: sum of 3 quarters · filed 2021-05-12 | $26.48M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $15.29M 10-K · filed 2020-03-26 | $16.31M derived: sum of 2 quarters · filed 2020-11-09 | $19.45M derived: sum of 3 quarters · filed 2020-11-09 | $22.50M 10-K · filed 2021-03-16 |
| 2019-09-30 | $1.02M 10-Q · filed 2020-11-09 | $4.16M derived: sum of 2 quarters · filed 2020-11-09 | $7.21M 10-Q · filed 2020-11-09 | $11.02M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $3.14M 10-Q · filed 2020-08-11 | $6.19M 10-Q · filed 2020-08-11 | $10.00M derived: sum of 3 quarters · filed 2020-08-11 | $12.04M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $3.05M 10-Q · filed 2020-05-11 | $6.86M derived: sum of 2 quarters · filed 2020-05-11 | $8.90M derived: sum of 3 quarters · filed 2020-05-11 | $10.57M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $3.81M 10-K · filed 2020-03-26 | $5.85M derived: sum of 2 quarters · filed 2020-03-26 | $7.51M derived: sum of 3 quarters · filed 2020-03-26 | $9.73M 10-K · filed 2020-03-26 |
| 2018-09-30 | $2.04M 10-K · filed 2020-03-26 | $3.71M derived: sum of 2 quarters · filed 2020-03-26 | $5.93M 10-Q · filed 2019-11-12 | $8.05M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-06-30 | $1.67M 10-K · filed 2020-03-26 | $3.89M 10-Q · filed 2019-08-12 | $6.01M derived: sum of 3 quarters · filed 2020-03-26 | $8.34M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-03-31 | $2.22M 10-K · filed 2020-03-26 | $4.34M derived: sum of 2 quarters · filed 2020-03-26 | $6.67M derived: sum of 3 quarters · filed 2020-03-26 | $8.75M derived: sum of 4 quarters · filed 2020-03-26 |
| 2017-12-31 | $2.12M 10-K · filed 2019-03-28 | $4.45M derived: sum of 2 quarters · filed 2019-03-28 | $6.53M derived: sum of 3 quarters · filed 2019-03-28 | $8.36M 10-K · filed 2019-03-28 |
| 2017-09-30 | $2.33M 10-K · filed 2019-03-28 | $4.41M derived: sum of 2 quarters · filed 2019-03-28 | $6.24M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $2.08M 10-K · filed 2019-03-28 | $3.91M 10-Q · filed 2018-08-13 | ||
| 2017-03-31 | $1.83M 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |